EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review)

Shuangcui Wang, Changyu Liu, Chenxin Yang, Yutong Jin, Qian Cui, Dong Wang, Ting Ge, Guixin He, Wentao Li, Guan Zhang, Aqing Liu, Ying Xia und 2 weitere

Oncology Letters · 26.09.2024 · 28 (6)

DOI: 10.3892/ol.2024.14700 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Letters, online erschienen am 26.09.2024. Verfasst von Shuangcui Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Experiment Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cells play an important role in cancer, and energy metabolism can determine both the proliferation and differentiation of T cells. The inhibition of immune checkpoint molecules programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) are a promising cancer treatment. In recent years, research on CD28 has increased. Although numerous reports involve CD28 and its downstream PI3K/AKT/mTOR signaling mechanisms in T cell metabolism, they have not yet been elucidated. A literature search strategy was used for the databases PubMed, Scopus, Web of Science and Cochrane Library to ensure broad coverage of medical and scientific literature, using a combination of keywords including, but not limited to, 'lung cancer' and 'immunotherapy'. Therefore, the present study reviewed the interaction and clinical application of the PD-1/CTLA-4/CD28 and PI3K/AKT/mTOR pathways in T cells, aiming to provide a theoretical basis for immunotherapy in clinical cancer patients.

Schlagwörter

Stichwörter der Autor:innen

PI3K/AKT/mTORT cellscancermetabolismprogrammed cell death protein 1/cytotoxic T-lymphocyte associated protein 4/CD28proliferation

Autor:innen und Institutionen

  • Medical Experiment Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
  • National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 301617, P.R. China.
  • Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
  • School of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.
  • School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R. China.

Zitieren

APA

Wang, S., Liu, C., Yang, C., Jin, Y., Cui, Q., Wang, D., Ge, T., He, G., Li, W., Zhang, G., Liu, A., Xia, Y., Liu, Y., & Yu, J. (2024). PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review). Oncology Letters, 28(6). https://doi.org/10.3892/ol.2024.14700

Vancouver

Wang S, Liu C, Yang C, Jin Y, Cui Q, Wang D, et al. PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review). Oncology Letters. 2024;28(6). doi:10.3892/ol.2024.14700

BibTeX
@article{Wang2024,
  author = {Wang, Shuangcui and Liu, Changyu and Yang, Chenxin and Jin, Yutong and Cui, Qian and Wang, Dong and Ge, Ting and He, Guixin and Li, Wentao and Zhang, Guan and Liu, Aqing and Xia, Ying and Liu, Yunhe and Yu, Jianchun},
  title = {PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (Review)},
  journal = {Oncology Letters},
  year = {2024},
  volume = {28},
  number = {6},
  doi = {10.3892/ol.2024.14700}
}
Kostenlos starten →